Drug Profile
Anti-N-Glycolyl-GM3 monoclonal antibody - CIMAB
Alternative Names: 14F7; 14F7 humanised mAb; 14F7h; Anti-N-Glycolyl-GM3 antibody 14F7; Humanised monoclonal antibody 14F7; Monoclonal antibody 14F7Latest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator Center of Molecular Immunology
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for preclinical development in Cancer in Cuba (Parenteral)
- 28 Jun 2018 Clinical development planned for Cancer, including Solid tumours and B-cell lymphoproliferative syndrome (RPCEC00000266; RPCEC00000204)
- 21 May 2018 Center of Molecular Immunology plans a phase I/II trial for B-cell lymphoproliferative syndrome (Second-line therapy or greater) in Cuba (RPCEC00000266)